



ASX ANNOUNCEMENT

18 December 2018

Company Announcements Office
ASX Limited
Exchange Centre
20 Bridge Street
SYDNEY NSW 2000

NOTICE UNDER ASX LISTING RULE 3.10.5A

CardieX Limited ("CardieX" or the "Company") has issued a total of 98,333,333 fully paid ordinary shares to investors (Placement). The Placement was completed on 14 December 2018 and announced to the market on 6 December 2018.

Of the 98,333,333 fully paid ordinary shares issued, 20,210,514 were issued under ASX Listing Rules 7.1A available capacity and the balance of 78,122,819 were issued under ASX Listing Rule 7.1.

Pursuant to ASX Listing Rule 3.10.5A, the Company provides the following information in relation to the Placement made under ASX Listing Rule 7.1A.

- a) The dilutive effect of the Placement on existing shareholders of the Company is as follows:

	Shares	Dilution
Shares on issue pre Placement	532,818,793	
Shares issued under LR 7.1 capacity	78,122,819	12.38%
Shares issued under LR 7.1A capacity	20,210,514	3.2%
Total Shares on issue post Placement	631,152,126	
Total dilution effect		15.58%

Details of the Company's issued capital following the completion of the Placement held by pre- Placement and new shareholders are as follows:

	Shares	Percentage
Pre-Placement shareholders who did not participate in the Placement	431,817,088	74.90%
Pre-Placement shareholders who did participate in the Placement	101,001,705	17.52%
New shareholders who participated in the Placement	43,700,000	7.58%



- b) The equity securities were issued for cash consideration. The Company issued the securities as a Placement under rule 7.1A in order to assist in the funding of CardieX's further investment into inHealth and was the most efficient mechanism for raising funds at the time.
- c) There was no underwriting for this Placement.
- d) The capital raising was led by Taylor Collison who charged a total fee of 6% comprising a selling and management fee (excluding GST) for the Placement.

A handwritten signature in blue ink, appearing to read "Jarrod White", with a large, stylized flourish at the end.

Jarrod White
Company Secretary | Chief Financial Officer

Chief Financial Officer
Jarrod White

jwhite@cardiex.com

Investor Relations

Peter Taylor

Ph: +61 412 036 231

peter@nwrcommunications.com.au

About CardieX

CardieX is a global health technology company that develops digital and device based solutions for large-scale population health disorders. The Company's XCEL device is the world leader in measuring "central blood pressure" which is considered essential for the management of hypertension and related cardiovascular disorders. CardieX also has a joint venture partnership with Blumio, Inc in Silicon Valley for the development of a radar-based blood pressure sensor incorporating CardieX technology. In November 2018 CardieX entered into an agreement with inHealth Medical, Inc allowing CardieX to acquire up to 50.5% of inHealth by way of a convertible note.